Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 71Carcinoma, Non-Small-Cell Lung 69Multiple Myeloma 55Prostatic Neoplasms 54Colorectal Neoplasms 42Leukemia, Myeloid, Acute 39Neoplasms 38Melanoma 34Lymphoma 33Ovarian Neoplasms 30Lymphoma, Non-Hodgkin 29Lung Neoplasms 28Squamous Cell Carcinoma of Head and Neck 27Sarcoma 27Neoplasm Metastasis 25Carcinoma, Hepatocellular 24Pancreatic Neoplasms 23Endometrial Neoplasms 23Glioma 22Carcinoma, Renal Cell 22Lymphoma, Large B-Cell, Diffuse 21Hodgkin Disease 21Recurrence 20Leukemia, Lymphocytic, Chronic, B-Cell 20Head and Neck Neoplasms 20Urinary Bladder Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Myelodysplastic Syndromes 18Esophageal Neoplasms 17Hematologic Neoplasms 16

Interventions

abemaciclib 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Spinal Cord Neoplasms × 30 days × Clear all
NCT06413706 2026-05-22

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Eli Lilly and Company

Phase 2 Active not recruiting
45 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡